reason report
novaseq placement exceed expect near-term pt
bottom line remain op believ lower
sequenc cost competit among custom continu
drive novaseq product upgrad cycl year
launch base proprietari work recent lab check
rais forecast expect novaseq instal exceed
instrument vs consensu prior estim
revenu higher street
higher remain confid instrument
place also note novaseq revenu recognit depend
number factor includ custom receiv instrument
instal engin time phi control run valid
run custom sign-off metric make challeng
obtain precis number given confid novaseq
rais revenu quarter long-term growth
estim also inch pt move
novaseq placement like exceed estim base
custom check analysi believ instal
novaseq quarter recal guid instal
year forecast appear us
also pace instal appropri hope deliv
novaseq quarter easi task given variabl custom
demand import note upgrad novaseq lower
cost/gb data option necess custom tri
compet market continu see novaseq multi-year
replac cycl work tier custom high low
volum still new sequenc custom
novaseq consum pull-through still room grow
believ novaseq util consum pull-through still room
grow given street novaseq consum still materi
estim remain confid novaseq pull-through
exceed repres util across
novaseq flowcel compar util hiseq histor
much higher util hiseq aka genom center
high volum custom still transit mid-volum lab
start upgrad believ novaseq rapidli
adopt mid-volum custom requir instrument
continu see larg custom grail mp
other purchas instrument grail expect
one largest custom novaseq
current run full capac believ purchas
run patients-strong strive breast cancer
size data set per patient sampl make sequenc heavi assay
compani inform leerink partner llc research
revenu mm ep exclud charg amort intang
net debt total capit
price-to-earnings lt ep growth
life scienc tool diagnost
pleas refer page import disclosur price chart analyst certif
rate share outperform price target view
custom compet race reduc sequenc cost
manifest novaseq order believ sequenc market number
sampl depth coverag expand dramat next year novaseq
drive signific reduct sequenc cost hiseq
novaseq flow cell novaseq set path reach research grade
genom longer term price beyond high throughput platform also continu
drive double-digit growth desktop system includ nextseq essenti key high
growth market includ non-invas pre-nat test nipt oncolog continu
domin sequenc market world-wide address market size life
scienc genet test reproduct health oncolog market share revenu
market share sequenc unit believ ilmn market share accuraci
throughput enterpris level servic product factor continu keep
custom bound despit custom consid higher price still
direct strong competit sight somewhat unbound market believ
continu domin next-gen sequenc keep drive sequenc cost lower lead
elast demand sampl deeper sequenc need
novaseq placement like exceed consensu estim
remain outperform believ lower sequenc cost competit among
custom reduc cog continu drive novaseq product upgrad cycl
year launch recent extens proprietari work custom lab check
confirm like place novaseq instrument quarter vs
consensu model prior estim result full-year revenu
estim higher street higher given
confid novaseq rais revenu estim
lt growth estim also inch slightli pt move
flexibl revenu recognit
remain confid instrument place also import note
novaseq revenu recognit depend number factor includ custom receiv
instrument placement lab instal engin
go around time phi sequenc control run use calibr
instrument valid run might need diagnost lab final custom
sign-off metric make challeng obtain precis instal number
mani metric within control believ flexibl
revenu recognit instrument though expect instal quarter exceed
instrument would surpris abl recogn instrument
juli vs june
elast demand continu play
elast demand remain central ilmn thesi believ continu play
reduct cost sequenc cost/gb drive market expans novaseq
deliv sequenc cost half hiseq cost faster turnaround time
thu expand output lower cost introduct novaseq custom
gain lower sequenc cost near novaseq platform
design deliv genom long-term remain confid
deliv next gener flow cell provid even-larg capac
figur elast demand across ilmn sequenc
take cant leav upgrad novaseq get nextseq
prior convers medacorp specialist suggest broader realiz among lab
novaseq must option lab compet peer
market also saw recent day link appear continu
realiz among lab shift novaseq inevit lower cost
sequenc drive lab switch novaseq settl
nextseq volum support novaseq project novaseq instal
continu rise moder expect above-averag shipment number
expect instal well end
expect flowcel road
believ signific headroom drive sequenc cost
leverag dens pack nanowel improv chemistri like manifest
version long-term believ improv could continu arriv
increas featur densiti flow cell done via improv chemistri
increas surfac area glass faster optic faster read/writ data broader
electron continu improv still see improv flow cell featur size pattern
nano-wel pack togeth glass surfac drive increasingli higher cluster densiti
drive output per flow cell
 nodiscounthiseq estim /gb like decreas denser flow cell improv chemistri novaseq inc
becom much better pace instal
appear us also pace instal appropri hope deliv
novaseq quarter easi task given variabl custom demand compar
hiseq instal per quarter vari significantli
continu see novaseq multi-year replac cycl work tier
custom high low volum still new sequenc custom come
believ increasingli becom consum stori novaseq provid
path genom make flow-cel upgrad far frequent instrument launch
novaseq architectur built support flow-cel upgrad everi flow cell launch
cost per gb come drive increas sequenc volum expect drive
overal consum higher remain doubt mind sequenc volum rise
market demand driven oncolog nipt popul studi broadli research
novaseq highli close system sequenc kit come differ configur
meter price structur provid lower cost per gb gigabas use higher
consum volum beyond also tire price contract provid
discount use higher volum
figur novaseq consum sequenc kit price discount
assess theoret practic output novaseq flowcel came
conclus blend novaseq pull-through could reach well steadi state
view figur potenti conserv consum ramp among lead high volum
custom could push consum pull-through number even higher broader
lower usag lab adopt novaseq long-term despit high theoret pull-through novaseq
conserv expect blend novaseq pull-through could lower
seen hiseq histor even low
util rate see estim practic pull-through novaseq rang
flow cell flow cell
run anywher quot list price depend
cycl per run run time month would impli mani lab
expect spend roughli per month also high volum lab
run flow cell higher cost per run well either way tier
price structur flow-cel suggest despit lower volum
higher price make differ continu drive consum
estim higher expand market
figur flowcel output util scenario
hi-vol util lo-vol util pull-thru discount pull-thru undiscount pull-thru discount pull-thru undiscount box hi-vol box lo-vol pull-thru hi-vol lab pull-thru lo-vol lab pull-thru per cell pull-thru rate per average pull-thru per cell usag multi-unit multi-unit gb per per run run per pull-thru pull-thru pull-thru pull-thru pull-thru pull-thru pull-thru pull-thru pull-thru assum util practic inc
see sequenc market expand next year believ everyon
develop countri sequenc form fashion avenu
nipt pre-marit carrier screen consum genom inherit diseas liquid biopsi
screen oncolog unexplor market asid inevit market satur
bound happen long-term believ investor like continu focu near-
term ramp novaseq consum though street inch steadili novaseq
consum estim project novaseq consum revenu reach even higher
current street estim potenti pass
figur novaseq consum revenu project suggest upsid street estim
also believ research grade genom go closer expect
elast demand remain strong lab still desir even cheaper sequenc
much lower price believ capabl deliv via next
gener flow cell believ realiz price per gb trend
time expect sequenc market continu expand aggress
remaind clinic sequenc remain forefront
share current trade price-to-earnings consensu ep averag
life scienc tool lst group multipl note potenti unbound
market opportun major popul develop develop world
touch sequenc form test next year use dcf
analysi beta long-term growth rate wacc arriv
price target revis estim believ remain strong forc
sequenc market see gradual declin revenu growth
outer year addit believ long-term growth rate conserv
estim given sequenc repres somewhat unbound market opportun
view still applic continu explor beyond current one
risk valuat
margin profil would face downward pressur given new entrant innov competitor
understand domin market share genom sequenc industri
tmo ion torrent main competit believ major
competit near term product instal expens
competitor given monopoli howev custom balk price major
innov develop futur expect gross oper margin
declin given competit note occupi market share industri
instal base due expens equip instal highlight
import price consum elast product
affect reimburs decis medicar although posit cash
flow critic mass instal base demand genom test product
affect reimburs rate declin reimburs like lead lower demand
product activ turn would affect usag consum product
seen effect reimburs rate chang peer genom test industri
drop would certainli impact revenu believ ilmn growth profil could
significantli slow reimburs rate lower would like contribut
regul fda could major impact revenu well current
sell diagnost product laboratori consid laboratori develop test
ldt fda yet regul ldt due prolifer product industri
fda may revers cours regul ldt addit product requir fda
approv intend use diagnosi diseas expand
product purpos subject greater test complianc standard
increas oper expens believ addit regul ilmn ldt
research-us product would result risk estim
high level capit expenditur involv oper mean disrupt capital-expenditure
spend could lead slower growth level capital-expenditure need launch support new
product import growth slight delay instrument shipment
consum could caus guidanc miss miss guidanc close
one less hiseqx system anticip given small room error
one deal leverag capital-expenditure maintain oper risk
servic
good sold
interest expens incom
add net incom attribut non-control interest
net incom attribut
sg sale
 sale
oper expens sale
sg revenu
 revenu
compani report leerink partner estim
